Clinical trial
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02231723 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2014
- Completion date
- June 30, 2020
- Enrollment
- 139 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic pancreatic adenocarcinoma